-
Product Insights
Brain Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Brain Cancer - Drugs In Development, 2023’, provides an overview of the Brain Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Brain Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Neuroblastoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuroblastoma - Drugs In Development, 2023’, provides an overview of the Neuroblastoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuroblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Diphtheria + Pertussis (Acellular) + Tetanus) Vaccine 2 in Tetanus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Diphtheria + Pertussis (Acellular) + Tetanus) Vaccine 2 in Tetanus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.(Diphtheria + Pertussis (Acellular) + Tetanus) Vaccine...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LUNA-18 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LUNA-18 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LUNA-18 in Solid Tumor Drug Details: LUNA-18 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Temozolomide in Medulloblastoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Temozolomide in Medulloblastoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Temozolomide in MedulloblastomaDrug Details:Temozolomide (ORP-005) is under development for the treatment of pediatric cancers...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – B-4T2001 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. B-4T2001 in Non-Small Cell Lung Cancer Drug Details: B4T2-001 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INB-100 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.INB-100 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Drug Details:INB-100 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Temozolomide in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Temozolomide in Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Temozolomide in Glioblastoma Multiforme (GBM) Drug Details:Temozolomide (ORP-005) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Temozolomide in Neuroblastoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Temozolomide in Neuroblastoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Temozolomide in Neuroblastoma Drug Details:Temozolomide (ORP-005) is under development for the treatment of pediatric...